There is evidence that fingolimod works by targeting astrocytes that give rise to increased levels of acid sphingomyelinase (ASM) in MS brain lesions where it has an anti-inflammatory effect [146,152]. The gene discussed is SMPD1; the disease is myeloid sarcoma.